Bio-Rad Laboratories, Inc. filed a Form 8-K on November 4, 2026, announcing its financial results for the quarter ended September 30, 2026, and furnishing a press release and supplemental earnings presentation as exhibits.

Key Highlights

  • Reporting period: Financial results cover the fiscal quarter ended September 30, 2026.
  • Two share classes listed: Class A Common Stock (NYSE:BIO) and Class B Common Stock (NYSE:BIO.B), both traded on the New York Stock Exchange.
  • Press release furnished: Exhibit 99.1 contains the earnings press release dated November 4, 2026.
  • Supplemental materials furnished: Exhibit 99.2 is a Supplemental Earnings Presentation dated November 4, 2026, posted to the company's Investor Relations section under "Events and Presentations."
  • Signed by CFO: Roop K. Lakkaraju, Executive Vice President and Chief Financial Officer, signed the filing on behalf of the registrant.
  • Not "filed" for Section 18 purposes: According to the filing, the current report and its exhibits "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Bio-Rad Laboratories Discloses Q3 2026 Operational Results Under Items 2.02 and 7.01

Bio-Rad Laboratories, Inc., a Delaware-incorporated life science and diagnostics company headquartered at 1000 Alfred Nobel Drive, Hercules, California, filed this current report to announce its third-quarter 2026 financial results. The company disclosed the announcement under Item 2.02, Results of Operations and Financial Condition, as required when a registrant publicly releases material non-public information about completed fiscal periods.

Under Item 7.01, Regulation FD Disclosure, the company reported that it also posted a Supplemental Earnings Presentation on November 4, 2026, covering the same quarter. The filing identifies this presentation as Exhibit 99.2 and notes that it was made available in the Investor Relations section of the company's website under the subheading "Events and Presentations." The filing expressly incorporates the Item 7.01 disclosure by reference into Item 2.02.

The filing carries Commission File Number 001-07928 and lists two classes of common stock, each with a par value of $0.0001 per share. Both classes are registered on the New York Stock Exchange, with Class A trading under the symbol BIO and Class B under BIO.B. The registrant confirmed it is not an emerging growth company. The document was executed by Roop K. Lakkaraju in his capacity as Executive Vice President and Chief Financial Officer.

What Was Disclosed

Bio-Rad Laboratories furnished a press release and a Supplemental Earnings Presentation covering results for the quarter ended September 30, 2026, through a Form 8-K filed November 4, 2026, signed by CFO Roop K. Lakkaraju. The exhibits are furnished, not filed, under the Exchange Act.